Board of Directors

COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT

 

The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.

 

The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.

 

MEMBERS OF THE BOARD:

newport_small
lorne2
jbell
eborenstein
Ken Newport
Chair, Board of Directors
Dr. Lorne Babiuk
Vice-President, Research, University of Alberta
Dr. John Bell
Scientific Director, BioCanRx
Senior Scientist, The Ottawa Hospital
Professor, uOttawa
Ela Borenstein
Program Director
Business Development Bank of Canada (BDC)
edouville
cearle
kessabar
dlynkowski
Dr. Elizabeth Douville
Founder and Managing Partner, AmorChem Venture Fund
Craig Earle
Vice-President, Cancer Control at the Canadian Partnership Against Cancer
Karimah Es Sabar
Chief Executive Officer & Partner, Quark Venture Inc.

Debra Lynkowski
Chief Operating Officer
The Ottawa Hospital Research Institute
kmacdonald
bunderdown
Kendra MacDonald
Partner, Deloitte
Brian J. Underdown, Ph.D.
Venture Partner, Lumira Capital
Dr. Christine Williams
Deputy Director, Ontario Institute for Cancer Research (OICR)
Russell Williams
Vice President, Government Relations and Public Policy, Diabetes Canada and Special Counsel, The JBL Group

 

EX-OFFICIO MEMBERS (NON-VOTING)

 

smichaud
Dr. Stéphanie Michaud
President and CEO, BioCanRx
Secretary, Board of Directors

 

OBSERVERS

 

Alex Pigeon
Senior Program Manager, Networks of Centres of Excellence